Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)

Epidermolysis Bullosa Simplex Clinical Trial

Official title:

An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03154333
• Other study ID #: CCP-020-301
• Status: Terminated
• Phase: Phase 2
• Start date: June 1, 2017
• Est. completion date: October 31, 2018

Study information

• Verified date: October 2019
• Source: Castle Creek Pharmaceuticals, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Epidermolysis bullosa simplex (EBS) is a rare genetic skin disease characterized by fragility of the skin and mucous membranes resulting in painful blisters and erosions after minor trauma. The purpose of this study is to compare the efficacy of diacerein 1% ointment to vehicle ointment when applied once-daily for 8 weeks in subjects with EBS.

Description:

The study is an international, multicenter, randomized, double-blind, vehicle-controlled, parallel group study to evaluate the safety and efficacy of diacerein 1% ointment for the treatment of subjects with EBS. Participants were assigned to study groups receiving either diacerein 1% ointment or vehicle ointment for 8 weeks, followed by an 8 week follow-up period. Approximately 80 subjects were to be randomized to one of the 2 treatment groups.

The primary objective of this study is to compare the efficacy of diacerein 1% ointment to vehicle ointment based on reduction in body surface area (BSA) of EBS lesions being treated when applied once-daily for 8 weeks in subjects with EBS. The secondary objectives are to compare the effects of diacerein 1% ointment to vehicle ointment in subjects with EBS in changes in Investigator Global Assessment (IGA) scores, pain, pruritus, mobility, and safety and tolerability.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 54
• Est. completion date: October 31, 2018
• Est. primary completion date: October 15, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 4 Years and older

Eligibility

Key Inclusion Criteria:

• Subject is at least 4 years of age at Screening

• Subject has a documented genetic mutation consistent with EBS. Gene mutations acceptable for inclusion are as follows: KRT5, KRT14, PLEC1, TGM5, PKP1, DSP, FERMT1, EXPH5, DST, KLHL24.

• Subject has an Assessment Area of EBS lesions to be treated, that is =2% body surface area (BSA) and the EBS lesions are in one or both of the following body areas:

• Localized: plantar and/or palmar areas

• Generalized: arms, legs, torso, hands and feet

• Subject's EBS lesions in the Assessment Area have an Investigator's Global Assessment (IGA) score of =3

• Subject/caregiver agrees to not use any topical therapies other than the study medication that might influence the status of the EBS lesions during the duration of the study

• Subject is non-pregnant as confirmed by a negative urine pregnancy screen, non-lactating and is not planning for pregnancy during the study period

• If the subject is a woman of childbearing potential, agrees to use an approved effective method of birth control

• Subject is in good general health and free of any known disease state or physical condition which might impair evaluation of the EBS lesions or which exposes the subject to an unacceptable risk by study participation

Key Exclusion Criteria:

• Subject has EBS lesions to be treated that are infected

• Subject has used any diacerein containing product within 6 months prior to Screening

• Subject has used systemic immunotherapy or cytotoxic chemotherapy within 60 days prior to Screening

• Subject has used systemic steroidal therapy or has used topical steroidal therapy on the EBS lesions to be treated within 30 days prior to Baseline

• Subject has evidence of a systemic infection or has used systemic antibiotics within 7 days prior to Screening

• Subject is currently using systemic analgesics and/or anti-histamine therapy, for treatment of EBS lesions unless on a stable regimen (i.e., the same dosing regimen) for at least 4 weeks prior to Screening

• Subject has used any systemic diuretics or cardiac glycosides or any systemic product that might put the subject at undue risk

• Subject has used any topical product containing allantoin on the EBS lesions to be treated within 30 days prior to Screening

• Subject has a current malignancy, or a history of treatment for a malignancy within 2 years prior to Screening

• Subject currently has diabetes mellitus (HbA1c =6.5%) or controlled diabetes (HbA1c < 6.5%)

• Subject has a history of cardiac, hepatic (ALT and or AST >2x ULN, Total bilirubin >1.5x ULN at Screening), or renal disease (eGFR<30 ml/min/1.73 m^2)

• Subject has a non-EBS skin disease or condition (e.g., sunburn) that might put the subject at undue risk by study participation or interferes with the study medication application or the study assessments

Related Conditions & MeSH terms

• Epidermolysis Bullosa
• Epidermolysis Bullosa Simplex

Intervention

Drug:
• diacerein 1% ointment
diacerein 1% ointment administered topically
• A placebo ointment
vehicle ointment administered topically

Locations

Country	Name	City	State
Australia	Premier Specialists Pty Ltd; The Church	Kogarah	New South Wales
Austria	EB House Austria	Salzburg
France	CHU de NICE - Hopital de l'Archet II - Service de Dermatologie	Nice
France	Hopital Necker-Enfants Malades	Paris	Cedex
France	Hopital Saint Louis	Paris	Cedex
Germany	University Medical Center Freiburg	Freiburg
Israel	Tel Aviv Sourasky Medical Center	Tel Aviv
Netherlands	University Medical Center Groningen	Groningen
United Kingdom	Great Ormond Street Hospital	London	England
United Kingdom	St. Thomas' Hospital - St Johns Institute of Dermatology	London
United States	Children's Hospital Colorado	Aurora	Colorado
United States	University of North Carolina - Chapel Hill	Chapel Hill	North Carolina
United States	Medical University of South Carolina (MUSC)	Charleston	South Carolina
United States	Ann and Robert H. Lurie Children's Hospital of Chicago	Chicago	Illinois
United States	Northwestern University	Chicago	Illinois
United States	Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio
United States	University of Missouri Healthcare	Columbia	Missouri
United States	University of Minnesota	Minneapolis	Minnesota
United States	Stanford University	Palo Alto	California
United States	Phoenix Childrens Hospital	Phoenix	Arizona
United States	Children's Hospital of San Antonio ; Texas Dermatology and Laser Specialists	San Antonio	Texas
United States	Stony Brook University Medical Center	Stony Brook	New York

Sponsors (1)

Lead Sponsor	Collaborator
Castle Creek Pharmaceuticals, LLC

Countries where clinical trial is conducted

United States,  Australia,  Austria,  France,  Germany,  Israel,  Netherlands,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of Subjects Who Achieved = 60% Reduction in Body Surface Area (BSA) of EBS Lesions Within Assessment Area	Analysis of the proportion of subjects who achieved a =60% reduction in Body Surface Area (BSA) of EBS lesions within Assessment Area from Baseline to Week 8	Baseline to Week 8
Secondary	The Proportion of Subjects Who Achieved Success on the Investigator's Global Assessment (IGA)	The investigator's global assessment (IGA) is a five-point scale that is used for overall clinical assessment of severity of disease and classifies EBS-involved skin with a score ranging from 0-4. Success on the IGA was defined as =2-point reduction from Baseline to Visit 6 (Week 8).; IGA Scoring: 0 = Clear; 1 = Near Clear; 2 = Mild; 3 = Moderate; 4 = Severe; Minimum score = 0 Maximum score = 4; higher score = worse outcome	Baseline to Week 8